Celltrion

• Celltrion Revenue increased 35.2% YoY and operating profit surged 77.3%, marking the highest second-quarter performance in the company's history.
• High-margin newer portfolio exceeded 60% of total revenue, driving improved product mix and operating margin expansion to approximately 33%.
• Continued growth across the U.S. and Europe, supported by manufacturing expansion and pipeline advancement, further strengthens long-term growth foundation.

• Second consecutive quarter of outperforming market expectations, with further growth anticipated during the industry’s peak season in the second half.

   

INCHEON, South Korea – Celltrion today announced that it recorded preliminary consolidated revenue of KRW 1.3 trillion and operating profit of KRW 430 billion for the second quarter of 2026.

The results represent the strongest second-quarter performance in the company's history, with revenue increasing 35.2% year over year (YoY) and operating profit rising 77.3% YoY. Operating margin also improved significantly from 25% in the prior-year period to approximately 33%, demonstrating both continued top-line growth and improved profitability.

The quarter was particularly meaningful as it reflected not only higher sales but also qualitative grwoth driven by a greater contribution from high-margin products and structurally improved cost base. Following its strong first-quarter performance, Celltrion once again exceeded market expectations in the second quarter, underscoring the growing commercial impact of its business competitiveness.

The company also surpassed its previously announced second-quarter operating profit target of KRW 400 billion, which had been presented in its business outlook and management plan disclosed earlier this year, further strengthening confidence in the execution of its annual business plan.

Furthermore, considering the seasonal characteristics of the biosimilar industry, in which supply volumes for major national tenders and year-end inventory stocking demand are concentrated in the second half of the year, sales growth is expected to accelerate further during the remainder of the year. As a result, expectations are increasing that the company will exceed its full-year performance targets.

Transition toward High-Margin Young Portfolio Accelerates Structural Profitability Improvement

The strong performance was driven by the rapid growth of newly launched high-margin products in addition to solid sales of the company’s existing flagship products, accelerating the transformation of its product portfolio toward higher-value offerings.

Newer products including Remsima SC(marketed as Zymfentra in the U.S.), Yuflyma, and Steqeyma continued to deliver strong growth across major global markets, with the newer portfolio accounting for more than 60% of total revenue.

Zymfentra continued to achieve record-high prescription volumes in the United States, while Steqeyma rapidly expanded its market share and established itself among the leading competitors in the U.S. market. Avtozma and Stoboclo/Osenvelt also successfully gained market traction and are emerging as new growth drivers.

In Europe, Omlyclo continued to benefit from its first-mover advantage, while Vegzelma maintained its leading market position despite being a later entrant. Avtozma, Yuflyma, and Stoboclo/Osenvelt have also entered a phase of accelerated sales growth and are expected to become key contributors to second-half performance.

Profitability is also improving structurally. As most one-off costs associated with the merger have been resolved, the completion of high-cost inventory clearance, the end of R&D amortization, and improved manufacturing yield(Titer Improvement) collectively enhanced the company's cost competitiveness. Celltrion believes these profitability improvements are structural rather than temporary, supported by a higher-margin product mix and improved manufacturing efficiency, providing a solid foundation for sustainable earnings growth.

Strengthening Biosimilars, Novel Drug Pipeline, and Manufacturing Capacity to Support Long-Term Growth

Beyond its strong financial performance, Celltrion continues to strengthen its long-term growth platform. CT-P55, a biosimilar referencing Cosentyx for autoimmune diseases, is currently undergoing regulatory review in Korea, North America, and other key markets, while regulatory submissions for Herzuma SC are progressing sequentially across major global markets. Development of follow-on biosimilars referencing Keytruda and Darzalex is also progressing as planned. The company plans to expand its biosimilar portfolio to 18 products by 2030 and 41 products by 2038.

Novel drug development is also advancing steadily. CT-P70 and CT-P71 have both received U.S. FDA Fast Track Designation, accelerating their clinical development. Celltrion continues to expand R&D investment with the goal of securing a portfolio of 20 novel drug candidates by next year.

To support its expanding product portfolio, Celltrion is simultaneously strengthening its global manufacturing network. In Korea, the company is constructing Plants 4 and 5, adding 180,000 liters of drug substance (DS) manufacturing capacity to its existing 250,000-liter production base. In the United States, Celltrion recently announced a 75,000-liter expansion of its Branchburg manufacturing facility in New Jersey, increasing total U.S. capacity to 141,000 liters.

The expansion of its U.S. manufacturing site is expected to structurally mitigate tariff and supply chain risks while establishing a stronger foundation for the company's global contract manufacturing (CMO) business, ultimately supporting the company's long-term growth and enterprise value.

A Celltrion official said, "Our second-quarter performance demonstrates that our strategy of expanding the newer product portfolio while improving profitability has begun to deliver meaningful results." The official added, "We continue to strengthen our sustainable growth foundation by simultaneously expanding our product portfolio, enhancing manufacturing capabilities, and accelerating novel drug development. As major tender opportunities and continued momentum from newly launched products are expected to support stronger performance in the second half, we remain confident in delivering results that surpass those of the first half while further strengthening our competitiveness as a global biopharmaceutical leader.".